170 related articles for article (PubMed ID: 38477185)
1. Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.
Rodrigues NB; Chen-Li D; Di Vincenzo JD; Juneja A; Pinder BD; McIntyre RS; Rosenblat JD
J Psychopharmacol; 2024 Apr; 38(4):375-381. PubMed ID: 38477185
[TBL] [Abstract][Full Text] [Related]
2. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP
J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267
[TBL] [Abstract][Full Text] [Related]
3. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
Niciu MJ; Iadarola ND; Banerjee D; Luckenbaugh DA; Park M; Lener M; Park L; Ionescu DF; Ballard ED; Brutsche NE; Akula N; McMahon FJ; Machado-Vieira R; Nugent AC; Zarate CA
J Psychopharmacol; 2017 Dec; 31(12):1570-1577. PubMed ID: 29039254
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review].
Romeo B; Choucha W; Fossati P; Rotge JY
Encephale; 2017 Aug; 43(4):354-362. PubMed ID: 27623117
[TBL] [Abstract][Full Text] [Related]
6. Suicidality in treatment resistant depression: perspective for ketamine use.
Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Słupski J; Włodarczyk A; Górska N; Szarmach J; Szałach ŁP; Wiglusz MS; Krysta K; Cubała WJ
Psychiatr Danub; 2019 Sep; 31(Suppl 3):258-260. PubMed ID: 31488737
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
[TBL] [Abstract][Full Text] [Related]
8. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
9. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
[TBL] [Abstract][Full Text] [Related]
11. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression.
Parikh SV; Vande Voort JL; Yocum AK; Achtyes E; Goes FS; Nykamp L; Singh B; Lopez-Vives D; Sera CE; Maixner D; Tarnal V; Severe J; Bartek S; Tye SJ; Rico J; Stoppel CJ; Becerra A; Smart L; Miller CR; Frye MA; Greden JF; Bobo WV
J Affect Disord; 2024 Mar; 348():143-151. PubMed ID: 38142892
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
14. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
15. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
[TBL] [Abstract][Full Text] [Related]
16. Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.
Beanes G; Caliman-Fontes AT; Souza-Marques B; Silva HDS; Leal GC; Carneiro BA; Guerreiro-Costa LNF; Figueiredo AV; Figueiredo CAV; Lacerda ALT; Costa RDS; Quarantini LC
Clin Neuropharmacol; 2022 Nov-Dec 01; 45(6):151-156. PubMed ID: 36093918
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic.
Rosenblat JD; Lipsitz O; Di Vincenzo JD; Rodrigues NB; Kratiuk K; Subramaniapillai M; Lee Y; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Wong L; Mansur RB; McIntyre RS
Psychiatry Res; 2021 Sep; 303():114086. PubMed ID: 34246008
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
[TBL] [Abstract][Full Text] [Related]
19. Effects of treatment refractoriness and brain-derived neurotrophic factor Val66Met polymorphism on antidepressant response to low-dose ketamine infusion.
Chen MH; Lin WC; Tsai SJ; Li CT; Cheng CM; Wu HJ; Bai YM; Hong CJ; Tu PC; Su TP
Eur Arch Psychiatry Clin Neurosci; 2021 Oct; 271(7):1267-1274. PubMed ID: 33959800
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of ketamine response in treatment-resistant major depression.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
